We used AGS and MKN-28 cells because of reduced SHP-1 and preserved p-STAT3 expression. Western blot,
wound closure assay,
Matrigel invasion assay and 3-D culture invasion assay were performed. Pharmacologic inhibitor of SHP-1 and
siRNA were used for validation of the role of SHP-1.
RESULTS: We observed that
pantoprazole at 40, 80, and 160 μg/ml upregulated SHP-1 and downregulated p-STAT3 expression in a dose-dependent manner in AGS and MKN-28 cells. Furthermore,
pantoprazole significantly downregulated mesenchymal markers (Snail1 and
vimentin), upregulated epithelial marker (
E-cadherin), and inhibited migration and invasion of AGS and MKN-28 cells. To validate the role of SHP-1 in inhibition of STAT3 activity by
pantoprazole in
gastric cancer cells, we performed pharmacologic inhibition (
pervanadate) or knockdown of SHP-1 before
pantoprazole treatment, which significantly attenuated the suppression of p-STAT3 and anti-migration and invasion effect by
pantoprazole in AGS cells. In xenograft
tumor model,
tumor volume was significantly reduced by
intraperitoneal injection of
pantoprazole, with upregulation of SHP-1 and downregulation of p-STAT3, which were attenuated by concomitant injection of
pervanadate.
CONCLUSION: